[go: up one dir, main page]

IN2013CH05441A - - Google Patents

Download PDF

Info

Publication number
IN2013CH05441A
IN2013CH05441A IN5441CH2013A IN2013CH05441A IN 2013CH05441 A IN2013CH05441 A IN 2013CH05441A IN 5441CH2013 A IN5441CH2013 A IN 5441CH2013A IN 2013CH05441 A IN2013CH05441 A IN 2013CH05441A
Authority
IN
India
Prior art keywords
preparation
pharmaceutical compositions
same
stabilized pharmaceutical
solvates
Prior art date
Application number
Inventor
Chandrashekhar Kandi
Nagaprasad Vishnubhotla
Sreekanth Manikonda
Anil Kumar Reddy
Arjuna Rao Panchada
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Priority to IN5441CH2013 priority Critical patent/IN2013CH05441A/en
Priority to US14/544,126 priority patent/US20150157618A1/en
Publication of IN2013CH05441A publication Critical patent/IN2013CH05441A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.
IN5441CH2013 2013-11-26 2013-11-26 IN2013CH05441A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN5441CH2013 IN2013CH05441A (en) 2013-11-26 2013-11-26
US14/544,126 US20150157618A1 (en) 2013-11-26 2014-11-26 Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN5441CH2013 IN2013CH05441A (en) 2013-11-26 2013-11-26

Publications (1)

Publication Number Publication Date
IN2013CH05441A true IN2013CH05441A (en) 2015-05-29

Family

ID=53270042

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5441CH2013 IN2013CH05441A (en) 2013-11-26 2013-11-26

Country Status (2)

Country Link
US (1) US20150157618A1 (en)
IN (1) IN2013CH05441A (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103945A1 (en) * 2015-12-15 2017-06-22 Strides Shasun Limited Pharmaceutical compositions
TR201617984A2 (en) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN
JP2018104425A (en) * 2016-12-26 2018-07-05 日本ケミファ株式会社 Tablet containing dabigatran etexilate or a pharmaceutically acceptable salt thereof
JP2018184375A (en) * 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same
TR201722323A2 (en) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions of dabigatran
CN110354123B (en) * 2018-04-04 2023-11-24 上海汉都医药科技有限公司 Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
CN110354122B (en) * 2018-04-04 2023-07-28 上海汉都医药科技有限公司 Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
EP3787624A4 (en) * 2018-05-04 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DABIGATRAN ETEXILATE CAPSULE IN CAPSULE COMPOSITIONS
TR201905308A2 (en) * 2019-04-09 2020-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A CAPSULE FORMULATION OF DABIGATRAN ETEXILATE
JP2021014411A (en) * 2019-07-10 2021-02-12 日医工株式会社 Stable dabigatran etexilate preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
EP2155167A2 (en) * 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
BRPI0921479A2 (en) * 2008-11-11 2016-01-12 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved safety profile compared to conventional warfarin therapy
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition

Also Published As

Publication number Publication date
US20150157618A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
IN2013CH05441A (en)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12019500163A1 (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
MY200356A (en) Kras g12c inhibitors
MX2015012850A (en) Arginine methyltransferase inhibitors and uses thereof.
PH12019501639A1 (en) Jaki selective inhibitors
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
TN2014000155A1 (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
IN2014MN02658A (en)
IN2014MN02245A (en)
PH12016501462A1 (en) Neprilysin inhibitors
WO2014153495A3 (en) Novel stat3 inhibitors
IN2013MU03862A (en)
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
MX2015011178A (en) Intrathecal hydromorphone solutions having improved stability.
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
WO2016069542A3 (en) Lactone compounds and methods of making and using same
WO2020032885A3 (en) Capsule-in-capsule compositions of dabigatran etexilate
IN2013MU03308A (en)
IN2013MU03422A (en)
IN2013MU03309A (en)
IN2013MU03421A (en)